Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Jaguar Health Inc (JAGX)

Jaguar Health Inc (JAGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,627
  • Shares Outstanding, K 46,363
  • Annual Sales, $ 4,420 K
  • Annual Income, $ -32,150 K
  • 60-Month Beta 0.77
  • Price/Sales 7.68
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -64.34
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/18/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.25
  • Number of Estimates 1
  • High Estimate -0.25
  • Low Estimate -0.25
  • Prior Year -42.66
  • Growth Rate Est. (year over year) +99.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.64 +18.13%
on 10/14/19
1.58 -52.08%
on 09/24/19
-0.68 (-47.42%)
since 09/20/19
3-Month
0.64 +18.13%
on 10/14/19
2.01 -62.23%
on 07/22/19
-1.20 (-61.37%)
since 07/19/19
52-Week
0.64 +18.13%
on 10/14/19
39.55 -98.09%
on 10/22/18
-37.39 (-98.02%)
since 10/19/18

Most Recent Stories

More News
MicroCap Rodeo Investor Conference - Lineup for October 15 and 16, 2019

The MicroCap Rodeo's inaugural event is set for October 15, and 16, 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, the MicroCap Rodeo brings some of the best stories...

JAGX : 0.73 (-7.59%)
Jaguar Health Engages Firm to Explore Potential License Agreements and Collaborations for Mytesi in China

Jaguar Health Receives $1.75 Million in Proceeds from Warrant Exercise at an Exercise Price of $1.40

JAGX : 0.73 (-7.59%)
Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer

SAN FRANCISCO, CA / ACCESSWIRE / October 4, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that a License Termination and Settlement agreement ("LTSA") related to...

JAGX : 0.73 (-7.59%)
Thinking about buying stock in Jaguar Health, Microsoft, PepsiCo, Safe-T Group, or Tilray?

InvestorsObserver issues critical PriceWatch Alerts for JAGX, MSFT, PEP, SFET, and TLRY.

JAGX : 0.73 (-7.59%)
MSFT : 138.47 (+0.77%)
SFTTY : 2.0000 (-33.33%)
Jaguar Health Files Final Canalevia (Crofelemer) Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs

Reminder: Company to Host Investor Call October 3rd at 8 a.m. Eastern to Provide Updates Regarding Development of Mytesi® (Crofelemer) for the Potential Follow-on Indication of Cancer Therapy-Related...

JAGX : 0.73 (-7.59%)
Jaguar Health Subsidiary Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Application

SAN FRANCISCO, CA / ACCESSWIRE / September 30, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned, human-health focused subsidiary, Napo...

JAGX : 0.73 (-7.59%)
Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Mark S. King September 27, 2019 at 3 p.m. Eastern

SAN FRANCISCO, CA / ACCESSWIRE / September 26, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned, human-health focused subsidiary, Napo...

JAGX : 0.73 (-7.59%)
Jaguar Health to Host Investor Call October 3rd at 8 a.m. Eastern to Provide Updates Regarding Development of Mytesi for the Potential Follow-on Indication of Cancer Therapy-Related Diarrhea

SAN FRANCISCO, CA / ACCESSWIRE / September 24, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a conference call on Thursday, October...

JAGX : 0.73 (-7.59%)
Jaguar Health Comments on FDA's Decision to Set Packaging Limits for Anti-Diarrhea Medicine Loperamide (Imodium) to Encourage Safe Use

Mytesi® Novel Anti-Diarrheal Mechanism of Action Distinguished as Non-Opioid

JAGX : 0.73 (-7.59%)
Jaguar Health to Present at Ladenburg Thalmann Healthcare Conference September 24 in New York

SAN FRANCISCO, CA / ACCESSWIRE / September 19, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Lisa Conte, Jaguar's founder, president and CEO, will present at...

JAGX : 0.73 (-7.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade JAGX with:

Business Summary

Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing...

See More

Key Turning Points

2nd Resistance Point 0.86
1st Resistance Point 0.83
Last Price 0.73
1st Support Level 0.74
2nd Support Level 0.68

See More

52-Week High 39.55
Fibonacci 61.8% 24.69
Fibonacci 50% 20.10
Fibonacci 38.2% 15.50
Last Price 0.73
52-Week Low 0.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar